Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose corticosteroids in the critically ill patient. Current concept and future developments.

L B Hinshaw

    Acta Chirurgica Scandinavica. Supplementum
    |January 1, 1985
    PubMed
    Summary

    Corticosteroids show promise in treating severe sepsis/septic shock, particularly when combined with antibiotics, based on animal studies. Further human trials are needed to identify patient subgroups who may benefit from this therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Peritonitis in the baboon: a primate model which stimulates human sepsis.

    Shock (Augusta, Ga.)·2000
    Same author

    Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli--a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli.

    Thrombosis and haemostasis·1998
    Same author

    Lupus humoral autoimmunity induced in a primate model by short peptide immunization.

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research·1998
    Same author

    Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha.

    Journal of immunology (Baltimore, Md. : 1950)·1996
    Same author

    Sepsis/septic shock: participation of the microcirculation: an abbreviated review.

    Critical care medicine·1996
    Same author

    Comparison of the capacity of rhTNF-alpha and Escherichia coli to induce procoagulant activity by baboon mononuclear cells in vivo and in vitro.

    Shock (Augusta, Ga.)·1996

    Area of Science:

    • Critical Care Medicine
    • Pharmacology
    • Infectious Diseases

    Background:

    • Current evidence does not support corticosteroid use in cardiogenic, hemorrhagic, or septic shock in humans.
    • Concerns exist regarding the safety, appropriateness, and practicality of corticosteroid administration in severe sepsis/septic shock.
    • Animal studies demonstrate significant efficacy of high-dose corticosteroids with antibiotics in E. coli-induced shock.

    Purpose of the Study:

    • To investigate the potential human application of corticosteroid therapy in severe sepsis/septic shock.
    • To address conflicting results from previous clinical studies on corticosteroid effectiveness.
    • To identify specific human patient subgroups that may respond favorably to high-dose corticosteroid treatment.

    Main Methods:

    Related Experiment Videos

  • Review of existing clinical studies and animal research on corticosteroid use in shock and severe sepsis.
  • Emphasis on the need for carefully designed clinical trials.
  • Focus on identifying responsive patient subgroups.

    • Main Results:

    • No established findings support corticosteroid use in human cardiogenic, hemorrhagic, or septic shock.
    • Animal studies show positive outcomes with combined corticosteroid and antibiotic therapy.
    • Clinical study results regarding corticosteroid effectiveness in severe sepsis/septic shock are conflicting.

    Conclusions:

    • Urgent need for rigorous clinical studies to validate corticosteroid efficacy in specific human sepsis populations.
    • Potential for high-dose corticosteroids combined with conventional therapy in select severe sepsis patients.
    • Further research required to bridge the gap between animal model findings and human clinical application.